123 related articles for article (PubMed ID: 24205719)
21. Cholesterol in the plasma very low density lipoprotein fraction in patients with type III hyperlipoproteinemia: analysis of factors which modulate its concentration.
Sutherland WH; Janus ED; Nye ER; Grant S
Biochem Med Metab Biol; 1988 Jun; 39(3):305-11. PubMed ID: 3165001
[TBL] [Abstract][Full Text] [Related]
22. Variable expression of familial dysbetalipoproteinemia in apolipoprotein E*2 (Lys146-->Gln) Allele carriers.
de Knijff P; van den Maagdenberg AM; Boomsma DI; Stalenhoef AF; Smelt AH; Kastelein JJ; Marais AD; Frants RR; Havekes LM
J Clin Invest; 1994 Sep; 94(3):1252-62. PubMed ID: 8083367
[TBL] [Abstract][Full Text] [Related]
23. The effect of tibolone on the lipoprotein profile of postmenopausal women with type III hyperlipoproteinemia.
de Beer F; Smelt AH; van Vark LC; Hoogerbrugge N; Havekes LM; Gevers Leuven JA
J Intern Med; 2002 Feb; 251(2):148-55. PubMed ID: 11908467
[TBL] [Abstract][Full Text] [Related]
24. Influence of apolipoprotein E genotype on the reliability of the Friedewald formula in the estimation of low-density lipoprotein cholesterol concentrations.
Tremblay AJ; Bergeron J; Gagné JM; Gagné C; Couture P
Metabolism; 2005 Aug; 54(8):1014-9. PubMed ID: 16092050
[TBL] [Abstract][Full Text] [Related]
25. [From gene to disease; apolipoprotein E2 and familial dysbetalipoproteinemia].
Smelt AH
Ned Tijdschr Geneeskd; 2003 Jan; 147(4):157-9. PubMed ID: 12635547
[TBL] [Abstract][Full Text] [Related]
26. Type III hyperlipoproteinemia with xanthomas and multiple myeloma.
Burnside NJ; Alberta L; Robinson-Bostom L; Bostom A
J Am Acad Dermatol; 2005 Nov; 53(5 Suppl 1):S281-4. PubMed ID: 16227109
[TBL] [Abstract][Full Text] [Related]
27. Apo E variants in patients with type III hyperlipoproteinemia.
Civeira F; Pocoví M; Cenarro A; Casao E; Vilella E; Joven J; González J; Garcia-Otín AL; Ordovás JM
Atherosclerosis; 1996 Dec; 127(2):273-82. PubMed ID: 9125318
[TBL] [Abstract][Full Text] [Related]
28. Molecular mechanisms of type III hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype.
Kypreos KE; Li X; van Dijk KW; Havekes LM; Zannis VI
Biochemistry; 2003 Aug; 42(33):9841-53. PubMed ID: 12924933
[TBL] [Abstract][Full Text] [Related]
29. Expression of type III hyperlipoproteinemia in apolipoprotein E2 (Arg158 --> Cys) homozygotes is associated with hyperinsulinemia.
de Beer F; Stalenhoef AF; Hoogerbrugge N; Kastelein JJ; Gevers Leuven JA; van Duijn CM; Havekes LM; Smelt AH
Arterioscler Thromb Vasc Biol; 2002 Feb; 22(2):294-9. PubMed ID: 11834531
[TBL] [Abstract][Full Text] [Related]
30. Simvastatin in the effective reduction of plasma lipoprotein levels in familial dysbetalipoproteinemia (type III hyperlipoproteinemia).
Stuyt PM; Mol MJ; Stalenhoef AF; Demacker PN; Van 't Laar A
Am J Med; 1990 Jan; 88(1N):42N-45N. PubMed ID: 2368763
[TBL] [Abstract][Full Text] [Related]
31. Triglyceride-rich lipoproteins in chronic kidney disease patients undergoing maintenance haemodialysis treatment.
Homma K; Homma Y; Yamaguchi S; Shiina Y; Wakino S; Hayashi K; Hori S; Itoh H
Int J Clin Pract; 2012 Apr; 66(4):394-8. PubMed ID: 22420498
[TBL] [Abstract][Full Text] [Related]
32. [Apolipoprotein E].
Yamamura T
Nihon Rinsho; 1994 Dec; 52(12):3124-32. PubMed ID: 7853700
[TBL] [Abstract][Full Text] [Related]
33. Unusual xanthomas in a young patient with heterozygous familial hypercholesterolemia and type III hyperlipoproteinemia.
Feussner G; Dobmeyer J; Nissen H; Hansen TS
Am J Med Genet; 1996 Oct; 65(2):149-54. PubMed ID: 8911609
[TBL] [Abstract][Full Text] [Related]
34. Type III hyperlipoproteinemia in a child with hemolytic uremic syndrome.
Feussner G; Wingen AM; Ziegler R
Metabolism; 1990 Nov; 39(11):1196-9. PubMed ID: 2233282
[TBL] [Abstract][Full Text] [Related]
35. Polymorphisms in the apolipoprotein A5 (APOA5) gene and type III hyperlipidemia.
Evans D; Seedorf U; Beil FU
Clin Genet; 2005 Oct; 68(4):369-72. PubMed ID: 16143024
[TBL] [Abstract][Full Text] [Related]
36. Type III hyperlipoproteinemic phenotype in transgenic mice expressing dysfunctional apolipoprotein E.
Fazio S; Lee YL; Ji ZS; Rall SC
J Clin Invest; 1993 Sep; 92(3):1497-503. PubMed ID: 8376602
[TBL] [Abstract][Full Text] [Related]
37. Tuberous xanthomas associated with olanzapine therapy and hypertriglyceridemia in the setting of a rare apolipoprotein E mutation.
Sinnott BP; Mazzone T
Endocr Pract; 2006; 12(2):183-7. PubMed ID: 16690468
[TBL] [Abstract][Full Text] [Related]
38. A new approach for the detection of type III hyperlipoproteinemia by RLP-cholesterol assay.
Nakajima K; Saito T; Tamura A; Suzuki M; Nakano T; Adachi M; Tanaka A; Tada N; Nakamura H; Murase T
J Atheroscler Thromb; 1994; 1(1):30-6. PubMed ID: 9222866
[TBL] [Abstract][Full Text] [Related]
39. A young type III hyperlipoproteinemic patient associated with apolipoprotein E deficiency.
Mabuchi H; Itoh H; Takeda M; Kajinami K; Wakasugi T; Koizumi J; Takeda R; Asagami C
Metabolism; 1989 Feb; 38(2):115-9. PubMed ID: 2492364
[TBL] [Abstract][Full Text] [Related]
40. LDL composition in E2/2 subjects and LDL distribution by Apo E genotype in type 1 diabetes.
Murdoch SJ; Boright AP; Paterson AD; Zinman B; Steffes M; Cleary P; Edwards K; Marcovina SS; Purnell JQ; Brunzell JD;
Atherosclerosis; 2007 May; 192(1):138-47. PubMed ID: 16740268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
